Key result
Risk models integrating symptoms and biomarkers predict non-relapse mortality to guide acute GVHD treatment.
Why the study?
Despite advances in prevention, acute GVHD remains challenging to treat with risks of overtreatment, undertreatment, relapse, and steroid-related toxicities, highlighting the need for risk-adapted personalized therapy.
Early risk stratification using clinical symptoms and biomarkers in acute GVHD can enable personalized medicine and potentially improve treatment outcomes.
Answers are grounded in this paper and cite their sources.
Should not yet alter acute GVHD management; leaves open prospective validation of MAGIC-guided therapy.
急性移植片対宿主病(GVHD)は,同種造血幹細胞移植後の主要な合併症の一つである。GVHD予防法の進歩により重症例は減少しているが,依然として治療に難渋する症例は少なくない。全身ステロイドに反応した患者でも,GVHDの再燃や感染症などステロイド関連の有害事象に加え,原病の再発が問題となる。一部の患者では過剰治療や治療不足に陥っている可能性があり,リスクに応じた個別化医療が治療成績の向上に寄与する可能性がある。患者のリスク層別化には,臨床症状やバイオマーカーを用いる方法が提案されており,Mount Sinai Acute GVHD International Consortium(MAGIC)からは両者を統合したリスクモデルが報告された。今後は,これらのモデルを用いた個別化治療を目指す臨床試験の実施が期待される。
No takes yet. Share an insight, caveat, or question.
Yu Akahoshi (2025) conducted a review in Acute graft-versus-host disease (GVHD). Risk stratification using clinical symptoms and biomarkers was evaluated. Risk stratification models integrating clinical symptoms and biomarkers, such as the MAGIC composite score, have been developed to predict non-relapse mortality and guide individualized treatment in acute GVHD.
Synapse has enriched 10 related papers. Consider them for comparative context: